source Post navigation Diabetes Dialogue: Oral GLP-1 Orforglipron in ACHIEVE-1 Trial – HCPLive Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study – BioMed Central